0001051514-23-000022.txt : 20230630 0001051514-23-000022.hdr.sgml : 20230630 20230630164015 ACCESSION NUMBER: 0001051514-23-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230629 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STRATA Skin Sciences, Inc. CENTRAL INDEX KEY: 0001051514 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133986004 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51481 FILM NUMBER: 231062331 BUSINESS ADDRESS: STREET 1: 5 WALNUT GROVE DRIVE STREET 2: SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 BUSINESS PHONE: 215-619-3200 MAIL ADDRESS: STREET 1: 5 WALNUT GROVE DRIVE STREET 2: SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 FORMER COMPANY: FORMER CONFORMED NAME: MELA SCIENCES, INC. /NY DATE OF NAME CHANGE: 20100504 FORMER COMPANY: FORMER CONFORMED NAME: ELECTRO OPTICAL SCIENCES INC /NY DATE OF NAME CHANGE: 19971216 8-K 1 form_8-k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 29, 2023

STRATA Skin Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)

000-51481
(Commission File Number)

Delaware
13-3986004
(State or Other Jurisdiction of Incorporation)
(I.R.S. Employer Identification No.)

5 WALNUT GROVE DRIVE, SUITE 140
HORSHAM, Pennsylvania 19044
(Address of principal executive offices, including zip code)

(215) 619-3200
(Registrant’s telephone number, including area code)

NOT APPLICABLE
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 par value per share
SSKN
NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 3.01.          Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On June 29, 2023, STRATA Skin Sciences, Inc. (the "Company") received written notification (the "Notice") from The NASDAQ Stock Market ("NASDAQ") that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The Notice provides the Company with an initial period of 180 calendar days, or until December 26, 2023, to regain compliance with the listing rules. The Company will regain compliance if the closing bid price of its common stock is $1.00 per share or higher for a minimum period of ten consecutive business days during this compliance period, as confirmed by written notification from NASDAQ.

If the Company does not achieve compliance by December 26, 2023, the Company expects that NASDAQ would provide notice that its securities are subject to delisting from the NASDAQ Capital Market, unless an additional extension to regaining compliance is then available.

The Company will continue to monitor the closing bid price for its common stock and to assess its options for maintaining the listing of its common stock on the NASDAQ Capital Market in light of this Notice. The Company will consider all available options to regain compliance with the minimum bid requirements, including an application to NASDAQ for an extension of the compliance period or an appeal to a Hearings Panel should its closing bid price not have regained compliance during the compliance period.


Item 7.01.          Regulation FD Disclosure.

On June 30, 2023, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing that the Company’s board of directors appointed Dr. Uri Geiger, a current director to the position of Chairman of the Board of Directors effective on July 3, 2023. The full text of such press release is furnished as Exhibit 99.1 to this report.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.


Item 8.01          Other Events.

On June 29, 2023, the Company’s board of directors appointed Dr. Uri Geiger, a current director to the position of Chairman of the Board of Directors effective on July 3, 2023, based upon the recommendation of the Compensation/Nominating Governance Committee of the board of directors. Mr. Humphries will remain a member of the board.


Forward-Looking Statements

This Current Report on Form 8-K may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Investors are cautioned that there can be no assurance actual results or business conditions will not differ materially from those projected or suggested in


- 2 -

such forward-looking statements as a result of various factors. Forward looking statements include, but are not limited to, statements with respect to the plans, strategies and objectives of management for future operations; our ability to regain compliance with NASDAQ listing requirements relating to the bid price of our common shares within the compliance period and any extension thereof. Please refer to the risks detailed from time to time in the reports we file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021, as well as other filings on Form 10-Q and periodic filings on Form 8-K, for additional factors that could cause actual results to differ materially from those stated or implied by such forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.


Item 9.01.          Financial Statements and Exhibits.
 

(d)          Exhibits.

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:

104          Cover Page Interactive Data File (embedded within the Inline XBRL document).





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



STRATA SKIN SCIENCES, INC.

Dated: June 30, 2023
By:    /s/ Christopher Lesovitz          
Christopher Lesovitz
   Chief Financial Officer




- 3 -
 EX-99.1 2 ex_99-1.htm STRATA SKIN SCIENCES PRESS RELEASE DATED JUNE 30, 2023
EXHIBIT 99.1

STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors
 


HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation.

“I’m honored to assume the role of Chairman at this pivotal moment in STRATA’s growth,” said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. “I look forward to leveraging my experience and guiding the company towards an exciting future.”

Dr. Geiger currently serves on the Board and his experience includes more than 20 years as a leader in the medical technology industry, contributing to his extensive entrepreneurial, management and investment experience. In his current role, Mr. Geiger serves as the founder and managing partner of Accelmed, a lower middle-market private equity firm focused on acquiring and investing in mature U.S.-based, commercial stage healthcare technology companies.

“We are delighted to have Uri move into the position of Chairman of the Board of Directors,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences. “Uri has been on the Board for over five years, and his extensive experience and long-term investment in the Company will help advance us into the next phase of growth.”

“Uri’s profound understanding of STRATA’s business model and the medical technology landscape make him ideally positioned to lead our Board,” said Bill Humphries, Member of STRATA's  Board of Directors. “I am confident that his stewardship will propel STRATA to greater heights and yield significant benefits for our shareholders.”

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.




STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell an acne treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to dermatologist marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from the coronavirus, fiscal, and political factors, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
 

 

 
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
sskn@cg.capital
 


- 2 -
 EX-101.SCH 3 sskn-20230629.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sskn-20230629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 sskn-20230629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jun. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 29, 2023
Entity File Number 000-51481
Entity Registrant Name STRATA Skin Sciences, Inc.
Entity Central Index Key 0001051514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 13-3986004
Entity Address, Address Line One 5 WALNUT GROVE DRIVE
Entity Address, Address Line Two SUITE 140
Entity Address, City or Town HORSHAM
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19044
City Area Code 215
Local Phone Number 619-3200
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SSKN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 form_8-k_htm.xml IDEA: XBRL DOCUMENT 0001051514 2023-06-29 2023-06-29 false 0001051514 8-K 2023-06-29 STRATA Skin Sciences, Inc. 000-51481 DE 13-3986004 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044 215 619-3200 false false false false Common Stock, $0.001 par value per share SSKN NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

%WE8<.&7J M/P$ #P" / " 7@0 !X;"]W;W)K8F]O:RYX;6Q02P$" M% ,4 " 'A=Y6)!Z;HJT #X 0 &@ @ 'D$0 >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 'A=Y699!YDAD! M #/ P $P @ ')$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" 3% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://strataskinsciences.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form_8-k.htm ex_99-1.htm sskn-20230629.xsd sskn-20230629_lab.xml sskn-20230629_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form_8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form_8-k.htm" ] }, "labelLink": { "local": [ "sskn-20230629_lab.xml" ] }, "presentationLink": { "local": [ "sskn-20230629_pre.xml" ] }, "schema": { "local": [ "sskn-20230629.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sskn", "nsuri": "http://strataskinsciences.com/20230629", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "form_8-k.htm", "contextRef": "c20230629to20230629", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://strataskinsciences.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "form_8-k.htm", "contextRef": "c20230629to20230629", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://strataskinsciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001051514-23-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001051514-23-000022-xbrl.zip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